Barron's thoughts on HealthcareInvestors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the science—blockbuster obesity drugs, advances in cancer treatments, novel cell therapies—they’ll stay for the macro story, specifically a slowing economy and falling interest rates, which tend to favor the sector. “We are in a wonderful, magical moment in science—and investing,” says Eli Casdin, chief investment officer and founder of Casdin Capital, and a member of Barron’s 2024 Healthcare Roundtable.